BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20116116)

  • 1. Validation of functional imaging with pathology for tumor delineation in the prostate.
    Groenendaal G; Moman MR; Korporaal JG; van Diest PJ; van Vulpen M; Philippens ME; van der Heide UA
    Radiother Oncol; 2010 Feb; 94(2):145-50. PubMed ID: 20116116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility.
    Hambrock T; Fütterer JJ; Huisman HJ; Hulsbergen-vandeKaa C; van Basten JP; van Oort I; Witjes JA; Barentsz JO
    Invest Radiol; 2008 Oct; 43(10):686-94. PubMed ID: 18791410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for tumor delineation in the prostate peripheral zone.
    Groenendaal G; Borren A; Moman MR; Monninkhof E; van Diest PJ; Philippens ME; van Vulpen M; van der Heide UA
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e537-44. PubMed ID: 22197085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.
    Langer DL; van der Kwast TH; Evans AJ; Trachtenberg J; Wilson BC; Haider MA
    J Magn Reson Imaging; 2009 Aug; 30(2):327-34. PubMed ID: 19629981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
    Lowry M; Zelhof B; Liney GP; Gibbs P; Pickles MD; Turnbull LW
    Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer.
    Scherr MK; Seitz M; Müller-Lisse UG; Ingrisch M; Reiser MF; Müller-Lisse UL
    Eur J Radiol; 2010 Dec; 76(3):359-66. PubMed ID: 20471189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer.
    Sciarra A; Panebianco V; Salciccia S; Osimani M; Lisi D; Ciccariello M; Passariello R; Di Silverio F; Gentile V
    Eur Urol; 2008 Sep; 54(3):589-600. PubMed ID: 18226441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients.
    Groenendaal G; van den Berg CA; Korporaal JG; Philippens ME; Luijten PR; van Vulpen M; van der Heide UA
    Radiother Oncol; 2010 May; 95(2):185-90. PubMed ID: 20231041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion tensor magnetic resonance imaging of prostate cancer.
    Manenti G; Carlani M; Mancino S; Colangelo V; Di Roma M; Squillaci E; Simonetti G
    Invest Radiol; 2007 Jun; 42(6):412-9. PubMed ID: 17507813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology.
    Isebaert S; Van den Bergh L; Haustermans K; Joniau S; Lerut E; De Wever L; De Keyzer F; Budiharto T; Slagmolen P; Van Poppel H; Oyen R
    J Magn Reson Imaging; 2013 Jun; 37(6):1392-401. PubMed ID: 23172614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features.
    Langer DL; van der Kwast TH; Evans AJ; Plotkin A; Trachtenberg J; Wilson BC; Haider MA
    Radiology; 2010 May; 255(2):485-94. PubMed ID: 20413761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.
    Tanimoto A; Nakashima J; Kohno H; Shinmoto H; Kuribayashi S
    J Magn Reson Imaging; 2007 Jan; 25(1):146-52. PubMed ID: 17139633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated detection of prostatic adenocarcinoma from high-resolution ex vivo MRI.
    Madabhushi A; Feldman MD; Metaxas DN; Tomaszeweski J; Chute D
    IEEE Trans Med Imaging; 2005 Dec; 24(12):1611-25. PubMed ID: 16350920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.
    Puech P; Potiron E; Lemaitre L; Leroy X; Haber GP; Crouzet S; Kamoi K; Villers A
    Urology; 2009 Nov; 74(5):1094-9. PubMed ID: 19773038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.
    van Dorsten FA; van der Graaf M; Engelbrecht MR; van Leenders GJ; Verhofstad A; Rijpkema M; de la Rosette JJ; Barentsz JO; Heerschap A
    J Magn Reson Imaging; 2004 Aug; 20(2):279-87. PubMed ID: 15269954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging.
    Miao H; Fukatsu H; Ishigaki T
    Eur J Radiol; 2007 Feb; 61(2):297-302. PubMed ID: 17085002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment on: role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer.
    Hara N
    Eur Urol; 2008 Sep; 54(3):598-9. PubMed ID: 18226440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.